OMICS Group-Genetic Syndromes amp; Gene Therapy-7412-3-118
OMICS Group is an Open Access publication model that enables the dissemination of research articles to the global community. Thus, all articles published under Open Access can be accessed by anyone.

By: OMICSGroup I Articles

Continue reading here:
OMICS Group-Genetic Syndromes & Gene Therapy-7412-3-118 - Video

Recommendation and review posted by Bethany Smith

OMICS Group - Genetic Syndromes amp; Gene Therapy-7412-3-119
OMICS Group is an Open Access publication model that enables the dissemination of research articles to the global community. Thus, all articles published under Open Access can be accessed by anyone.

By: OMICSGroup I Articles

View original post here:
OMICS Group - Genetic Syndromes & Gene Therapy-7412-3-119 - Video

Recommendation and review posted by Bethany Smith

19 - Direction of Current Research - Interview with Dr. Veena Rao
For additional information visit http://www.cancerquest.org In this video, Dr. Veena Rao talks about the ultimate goal and direction of her research with gene therapy and BRACO1. To learn more about cancer and watch additional interviews, please visit the CancerQuest website at http://www.cancerquest.org

By: CancerQuest

See the original post here:
19 - Direction of Current Research - Interview with Dr. Veena Rao - Video

Recommendation and review posted by Bethany Smith

18 - Gene Therapy and Cancer Prevention - Interview with Dr. Veena Rao
For additional information visit http://www.cancerquest.org In this video, Dr. Veena Rao discusses how gene therapy can lead to better cancer prevention. To learn more about cancer and watch additional interviews, please visit the CancerQuest website at http://www.cancerquest.org

By: CancerQuest

Continue reading here:
18 - Gene Therapy and Cancer Prevention - Interview with Dr. Veena Rao - Video

Recommendation and review posted by Bethany Smith

17 - Gene Therapy - Interview with Dr. Veena Rao
For additional information visit http://www.cancerquest.org In this video, Dr. Veena Rao explains what gene therapy is, the different types of gene therapy, and how it is relevant with her research with the BRACO1 gene. To learn more about cancer and watch additional interviews, please visit the CancerQuest website at http://www.cancerquest.org

By: CancerQuest

Here is the original post:
17 - Gene Therapy - Interview with Dr. Veena Rao - Video

Recommendation and review posted by Bethany Smith

Personalized Medicine: Are We There Yet? by Marylyn Ritchie
A central goal of identifying genetic variation for complex human traits is using that data for treatment and prevention of common diseases. Learn where the state of the art is in using genetic information for personalizing our health care. Presented by Penn State #39;s Marylyn Ritchie on 2/9/2013.

By: PennStateScience

Read the original here:
Personalized Medicine: Are We There Yet? by Marylyn Ritchie - Video

Recommendation and review posted by sam

CMC Spinal Cord Injury Mela 2013 - Female staff
Part of the staff skit for the 2013 Spinal Cord Injury Mela - female staff dance I dont think i will win an Oscar for my performance

By: Charlie Hogg

More:
CMC Spinal Cord Injury Mela 2013 - Female staff - Video

Recommendation and review posted by sam

Aubrey de Grey - SENS Research Foundation - Regenerative Medicine - XFF 2012

By: Adam Ford

Read the rest here:
Aubrey de Grey - SENS Research Foundation - Regenerative Medicine - XFF 2012 - Video

Recommendation and review posted by sam

Cell Therapy Center Emcell
The World #39;s Largest Clinical Experience in Fetal Stem Cell Transplantation Stem Cell Treatment for Various Diseases And Conditions. Anti-Aging Treatment

By: emcellsite

Read the rest here:
Cell Therapy Center Emcell - Video

Recommendation and review posted by simmons

Public release date: 28-Feb-2013 [ | E-mail | Share ]

Contact: Karen Richardson krchrdsn@wakehealth.edu 336-716-4453 Wake Forest Baptist Medical Center

WINSTON-SALEM, N.C. Feb. 28, 2013 Researchers at Wake Forest Baptist Medical Center and colleagues have identified a special population of adult stem cells in bone marrow that have the natural ability to migrate to the intestine and produce intestinal cells, suggesting their potential to restore healthy tissue in patients with inflammatory bowel disease (IBD).

Up to 1 million Americans have IBD, which is characterized by frequent diarrhea and abdominal pain. IBD actually refers to two conditions ulcerative colitis and Crohn's disease in which the intestines become red and swollen and develop ulcers, probably as the result of the body having an immune response to its own tissue.

While there is currently no cure for IBD, there are drug therapies aimed at reducing inflammation and preventing the immune response. Because these therapies aren't always effective, scientists hope to use stem cells to develop an injectable cell therapy to treat IBD.

The research findings are reported online in the FASEB Journal (the journal of the Federation of American Societies for Experimental Biology) by senior researcher Graca Almeida-Porada, M.D., Ph.D., professor of regenerative medicine at Wake Forest Baptist's Institute for Regenerative Medicine, and colleagues.

The new research complements a 2012 report by Almeida-Porada's team that identified stem cells in cord blood that are involved in blood vessel formation and also have the ability to migrate to the intestine.

"We've identified two populations of human cells that migrate to the intestine one involved in blood vessel formation and the other that can replenish intestinal cells and modulates inflammation," said Almeida-Porada. "Our hope is that a mixture of these cells could be used as an injectable therapy to treat IBD."

The cells would theoretically induce tissue recovery by contributing to a pool of cells within the intestine. The lining of the intestine has one of the highest cellular turnover rates in the body, with all cell types being renewed weekly from this pool of cells, located in an area of the intestine known as the crypt.

In the current study, the team used cell markers to identify a population of stem cells in human bone marrow with the highest potential to migrate to the intestine and thrive. The cells express high levels of a receptor (ephrin type B) that is involved in tissue repair and wound closure.

View post:
Research supports promise of cell therapy for bowel disease

Recommendation and review posted by Bethany Smith

Durham, N.C. People with heart disease have more treatment options than ever. However, sometimes nothing gets rid of continued chest pain known as angina. Researchers say they are looking at a special stem cell therapy to help those patients.

Danny Darden, 49, has heart disease and frequent chest pain despite two years worth of every treatment, surgery and medication available to stop it.

If I walk around the block, I give out and have chest pains, he said.

Duke cardiologist Dr. Tom Povsic included Darden in a phase 3 trial looking for benefits of a special stem cell therapy to stimulate the growth of new vessels feeding blood to the heart.

In certain patients, the arteries can no longer be fixed, or bypass surgery can't be used to fix the arteries. And in those patients, novel therapies are sorely needed, Povsic said. So, the stem cells in this particular case are obtained from the patient themselves.

The cells, originating in the bone marrow, are stimulated and released into the blood stream, extracted and then administered directly into the heart through a special catheter.

Last week, I was injected with the stem cells, Darden said. I'm excited to be in it, because I feel it's going to work, and even if it (doesnt) work for me, it's going to work for other people.

The study is blind, meaning Darden may have received a fake infusion. Participants are followed for two years. A smaller previous study showed promising results.

The benefit that was seen in the early study far exceeds what was seen with many medicines that are approved for angina relief, Povsic said.

Researchers say if the stem cell therapy benefits are confirmed in patients with angina, it could also be studied in patients dealing with stroke, heart attack or heart failure.

Follow this link:
Duke doctor: Stem cell therapy might help heart disease patients

Recommendation and review posted by Bethany Smith

Making Natural Product Research Work: Bubpha Techapattaraporn
The experience of BIOTEC in natural product research and the collaboration with Novartis Bubpha Techapattaraporn -- Head of Biotechnology Research section (BIOTEC, Thailand) Genetic Engineering and Biotechnology, Thailand

By: ifpma

More:
Making Natural Product Research Work: Bubpha Techapattaraporn - Video

Recommendation and review posted by Bethany Smith

More colleges and universities are offering courses that incorporate personal genetic testing, the Associated Press reports. Harvard Medical School and the Stanford University School of Medicine have offered such courses as electives for a few years, but the course the AP highlights is aimed at undergraduates.

The University of Iowa is offering an honors seminar on personal genomics that includes the option to be tested through 23andMe. The AP adds that Duke University, Stanford University, the University of Illinois, and the University of Texas also offer personal genomics courses that take advantage of a 23andMe testing discount.

Jeff Murray, the professor teaching the class, "talked through the pros and cons of testing with students, and spent two class periods examining 23andMe's consent form," the AP says. He also told them to discuss the test with their families. A few students decided not to be tested.

Iowa freshman Bakir Hajdarevic tells the AP that he was nervous that he might find out about something deleterious in his DNA, but that he was also curious to learn more and that his curiosity won out. Hajdarevic learned that he's at increased risk for being lactose intolerant and a carrier for Alpha 1-antitrypsin deficiency.

"I was kind of scared going in, like, 'Oh my God, I might have a high risk factor for some kind of cancer'," he tells the AP. "But knock on wood, according to the test, I don't really have much to worry about."

Follow this link:
Campus Genetics

Recommendation and review posted by Bethany Smith

Public release date: 27-Feb-2013 [ | E-mail | Share ]

Contact: George Hunka ghunka@aftau.org 212-742-9070 American Friends of Tel Aviv University

Tel Aviv For the estimated 250 million people worldwide who suffer from rare diseases, there is little hope for diagnosis or treatment. Because each individual disease impacts so few people, hardly any funding is allocated to research, leaving many without medical options. The US-based non-profit organization Rare Genomics Institute (RGI) is working to address this problem by "crowd-funding" allowing people to donate on the Internet towards genetic testing for individual children who are struggling with a rare disease.

Now, thanks to Dr. Noam Shomron of Tel Aviv University's Sackler Faculty of Medicine, RGI's vital mission has come to Israel the first international branch of the organization. Its online home is http://raregenomics.org/world_Israel.php, and it has launched its first appeal for two Israeli children at http://raregenomics.org/donors.php.

Based at the TAU-affiliated Sourasky Medical Center and Rabin Medical Center, RGI-Israel will help families with children impacted by rare genetic diseases find support and care through advanced genetic testing. The Israeli branch is run in collaboration with three of Israel's top geneticists, Drs. Lina Basel, Shay Ben-Shachar, and Hagit Baris.

The services that the organization provides are sorely needed in Israel, says Dr. Shomron, who is the director of Israel's RGI. Both Jewish and Arabic populations in Israel are plagued by a unique pool of genetic diseases. "There are decades of genetic puzzles in the Israeli population, and we are hoping to solve a few of them," he says, hoping that RGI-Israel will help provide the funding to support these families in need.

A community effort

A decade ago, the human genome was sequenced for the first time. The process cost over a billion dollars and took more than ten years to complete. But now a more advanced technology, deep sequencing, can sequence the entire human genome in a matter of days and at a less prohibitive cost. Dr. Shomron's TAU lab is a world leader in this field of research.

RGI's approach is straight-forward. It maintains online donation pages with pictures and personal stories of children in need of genetic testing for mutations as the first step toward treatment or a cure. Donors can then contribute to the cost of DNA testing for each individual child. "Deep sequencing costs around $1,500 per person now, and the fundraising goal for each child is less than $8,000, which is used for sequencing and confirmation of the genomes of the affected child and their relatives, depending on the family's genetic history and the genetics of the disease," says Dr. Shomron, who notes that Israeli families are already reaching out to RGI Israel for help. This allows families to avoid the difficult and expensive process of testing for mutations gene by gene.

One family, for example, has been plagued for generations by what appears to be mental retardation but the medical cause of this condition remains a mystery. "They have been living for many years without knowing what causes this problem in their family. They don't know whether their DNA is the cause and if it is, what mutation causes it," he says.

Read this article:
Crowd-sourced funding provides missing help for rare genetic diseases

Recommendation and review posted by Bethany Smith

Biblioteca Ambrosiana via LGPN

This codex of Homer's "Iliad" was produced in the late fifth century or early sixth century.

By Joel N. Shurkin Inside Science News Service

Scientists who decode the genetic history of humans by tracking how genes mutate have applied the same technique to one of the Western world's most ancient and celebrated texts to uncover the date it was first written.

The text is Homer's "Iliad," and Homer if there was such a person probably wrote it in 762 B.C., give or take 50 years, the researchers found. The "Iliad" tells the story of the Trojan War if there was such a war with Greeks battling Trojans.

The researchers accept the received orthodoxy that a war happened and someone named Homer wrote about it, said Mark Pagel, an evolutionary theorist at the University of Reading in England. His collaborators include Eric Altschuler, a geneticist at the University of Medicine and Dentistry of New Jersey, in Newark, and Andreea S. Calude, a linguist also at Reading and the Santa Fe Institute in New Mexico. They worked from the standard text of the epic poem.

The date they came up with fits the time most scholars think the "Iliad" was compiled, so the paper,published in the journal Bioessays,won't have classicists in a snit. The study mostly affirms what they have been saying, that it was written around the eighth century B.C.

That geneticists got into such a project should be no surprise, Pagel said.

"Languages behave just extraordinarily like genes," Pagel said. "It is directly analogous. We tried to document the regularities in linguistic evolution and study Homer's vocabulary as a way of seeing if language evolves the way we think it does. If so, then we should be able to find a date for Homer."

Who was Homer? It is unlikely there ever was one individual man named Homer who wrote the "Iliad." Brian Rose, professor of classical studies and curator of the Mediterranean section at the University of Pennsylvania Museum, said it is clear the "Iliad" is a compilation of oral tradition going back to the 13th century B.C.

View original post here:
Genetic tricks put a date on Homer's 'Iliad'

Recommendation and review posted by Bethany Smith

Biology Project- Gene Therapy

By: Jamie Lancaster

See the rest here:
Biology Project- Gene Therapy - Video

Recommendation and review posted by Bethany Smith

PORT ST. LUCIE, Fla.--(BUSINESS WIRE)--

Raymond F. Schinazi, Ph.D., DSc, a world leader in nucleoside chemistry and biology as well as the founder of five biotechnology companies, joins the Board of Directors of the Vaccine & Gene Therapy Institute of Florida (VGTI Florida), a leading nonprofit immunological research institute. Dr. Schinazi, a Professor of Pediatrics and Director of the Laboratory of Biochemical Pharmacology and of the Scientific Working Eradication Group at Emorys Center for AIDS Research, brings a wealth of expertise to assist VGTI Florida on its mission of Translating Research into Health.

Selected as a 2012 Charter Fellow of the National Academy of Inventors, a prestigious distinction awarded to academic inventors whose discoveries have made a tangible impact on the quality of life and welfare of society, Dr. Schinazi will inspire the VGTI Florida community and serve as an example of effective translational research. His experience in running biotech companies and obtaining patents will help the research institute navigate the licensing and commercialization challenges associated with bringing novel technologies to the market place.

As an influential scientist, inventor, educator, and entrepreneur, were extremely pleased that Dr. Schinazi is bringing his impressive array of experience to VGTI Florida, said Jay Nelson, Ph.D., Founder and Executive Director of the institute. His remarkable accomplishments include commercialized inventions that have revenues of over $2 billion per year; in fact, more than 94% of HIV-infected individuals take at least one of the medicines he invented, saving millions of lives, Dr. Nelson added.

Dr. Schinazi is a Senior Research Career Scientist at the Atlanta VA and also an adjunct professor at Georgia State University and the University of Miami. He serves as an advisor for the Schiff Center for Liver Diseases at the University of Miami, and is a Governing Trustee for the Foundation for AIDS Research (amfAR). He has served on the Presidential Commission on AIDS and has won many awards including the Georgia Biomedical Industry Growth Award and the Distinguished Scientist Award from the Hepatitis B Foundation. Dr. Schinazi was inducted into the Technology Hall of Fame of Georgia in March 2012, and he received the Intellectual Property Legends Award in October 2012.

He has co-authored more than 470 peer-reviewed papers and 7 books; and has secured more than 90 U.S. patents. Dr. Schinazi has served on the editorial board of several peer-reviewed journals, including Antimicrobial Agents and Chemotherapy, Antiviral Chemistry and Chemotherapy, Antiviral Research and Antiviral Therapy. His current research focuses on HIV, HBV and HCV eradication strategies.

He holds a Bachelor of Science, a Ph.D. and Doctor of Science degree in Chemistry from the University of Bath, England. Dr. Schinazi completed postdoctoral training in Pharmacology at Yale University and in Virology/Immunology from Emory University.

VGTI Florida

VGTI Florida is a leading immunological research institute that is on an urgent mission to transform scientific discoveries into novel treatments and cures for devastating chronic illnesses such as cancer, HIV/AIDS, influenza and infectious diseases. VGTI Florida is an independent non-profit 501(c)(3) organization located in the Tradition Center for Innovation in Port St. Lucie, Florida. For more information, please visit http://www.VGTIFL.org.

See the original post here:
Raymond F. Schinazi, Ph.D., D.Sc., Joins the Vaccine & Gene Therapy Institute of Florida Board of Directors

Recommendation and review posted by Bethany Smith

PORT ST. LUCIE, Fla.--(BUSINESS WIRE)--

The Vaccine & Gene Therapy Institute of Florida (VGTI Florida), a leading nonprofit immunological research institute, is pleased to announce the appointment of Robert L. Lord, Jr., J.D., B.C.S., F.A.C.H.E., to the Board of Directors. Mr. Lord is Senior Vice President, Legal Services and Chief Legal Officer of Martin Health System, which serves the residents of Floridas Treasure Coast. He is currently overseeing the construction and development of the new Martin Health System Campus located adjacent to VGTI Florida in the Tradition Center for Innovation in Port St. Lucie, Florida.

Many opportunities exist for collaboration between the lifesaving research of VGTI Florida researchers and the clinical trials conducted by doctors at Martin Health System. Both organizations are helping to improve the lives of people locally and around the world.

A board certified health law expert and healthcare executive, Mr. Lord is an administrator in Martin Health overseeing matters ranging from operations, corporate compliance, risk management and planning to litigation and governmental relations. He has been a resident of the Treasure Coast since 1969.

We welcome Roberts wide ranging health law background and his wealth of experience to the VGTI Florida Board of Directors, said Jay Nelson, Ph.D., founder and Executive Director of the institute. He has his finger on the pulse of the local community and will contribute greatly to the progress of VGTI Floridas research translation into the clinical environments.

Prior to joining Martin Health System, Mr. Lord was Shareholder in the law firm of Crary, Buchanan, Bowdish, Bovie, Lord & Roby, Chartered. His practice focused on both health and media law. Prior to specializing in media and health law, he had many years of experience as a civil trial attorney.

Mr. Lord holds a Bachelor of Science from Florida State University and he received his Juris Doctorate degree from Stetson University College of Law. He is board certified by The Florida Bar in Health Law and is a Fellow of the American College of Healthcare Executives.

His professional affiliations include The Florida Bar, American Health Lawyers Association, American College of Healthcare Executives, the bars of the Florida Supreme Court and the United States Supreme Court.

VGTI Florida

VGTI Florida is a leading immunological research institute that is on an urgent mission to transform scientific discoveries into novel treatments and cures for devastating chronic illnesses such as cancer, HIV/AIDS, influenza and infectious diseases. VGTI Florida is an independent non-profit 501(c)(3) organization located in the Tradition Center for Innovation in Port St. Lucie, Florida. For more information, please visit: http://www.VGTIFL.org

Read more here:
Attorney Robert L. Lord, Jr. Joins the Vaccine & Gene Therapy Institute of Florida Board of Directors

Recommendation and review posted by Bethany Smith

Beth H. T-11 Incomplete Spinal Cord Injury at Pressing On
This is a quick sample of some of the things we focus on during one-on-on training at Pressing On. Client is Beth and she is a T-11 Incomplete Spinal Cord Injury and the trainer is Stanley Arinze. For more information on our non-profit gym for neurological disorders, visit http://www.pressingontx.org or facebook.com/pressingontx

By: pressingontx

Read the original post:
Beth H. T-11 Incomplete Spinal Cord Injury at Pressing On - Video

Recommendation and review posted by sam

Spinal cord injury,weight lifting,Chest 90kg 200 lbs
Arnar Helgi Lrusson sci 2002 T2/3 complete This video is since 2013 visit my website http://www.wix.com

By: Arnar lrusson

Visit link:
Spinal cord injury,weight lifting,Chest 90kg 200 lbs - Video

Recommendation and review posted by sam

Back Up supports Toby, a young boy who developed spinal cord injury aged 3
Back Up supports Toby, a young boy who developed spinal cord injury aged 3 after an illness. Find out more at http://www.backuptrust.org.uk

By: BackUpTrust

More here:
Back Up supports Toby, a young boy who developed spinal cord injury aged 3 - Video

Recommendation and review posted by sam

Spinal Cord Injury Ontario Holds First Annual Windsor Roll and Bowl
We #39;ve got your back. You #39;ve got your future! Spinal Cord Injury Ontario champions excellence in service, advocacy and quality of life for people with spinal cord injuries. The commitment to their high quality of service and promoting the best quality of life possible, for those who have sustained an injury continued on Monday, as the organization held their first annual Windsor Roll in Bowl. Organizers of Monday #39;s event were hoping to raise upwards of $10000 to help support and strengthen the services they offer throughout the Windsor Essex County Region. Sheila O #39;Neill is the Community Development Officer for the organization and she shares the details of how those who have sustained a spinal cord injury can still live a productive and positive life after this dramatic change in both lifestyle and circumstances. While Johanna Beneteau a volunteer for SCI Ontario says it #39;s important to exhibit a true sense of empathy for people living with an injury in order to receive a full understanding of the experiences they endure on an ongoing basis. It #39;s all in my latest story for CFTV34.

By: Kevin McShan

More:
Spinal Cord Injury Ontario Holds First Annual Windsor Roll and Bowl - Video

Recommendation and review posted by sam

One week of poor sleep can disrupt hundreds of genes linked to stress, immunity and inflammation, research has shown.

Scientists think the discovery could explain why lack of sleep can have a devastating impact on health.

For the new study, researchers examined gene activity in 26 sleep-deprived volunteers.

They found that insufficient sleep had an impact on more than 700 genes. Some had their activity dampened, while others became extra-active.

Those affected included genes associated with the "body clock" cycle, metabolism, and immune and stress responses.

Poor sleep also altered chromatin - the DNA and protein "packaging" that plays an important role in gene regulation.

The researchers believe their findings may be particularly relevant to people working long hours in industrialised societies.

The scientists, led by University of Surrey sleep expert Professor Derk-Jan Dijk, analysed RNA - the messenger chemical that delivers coded "instructions" from the genes to cells - in the blood of volunteers.

Participants were exposed to a week of poor sleep during which they slept no more than six hours a night. At the end of this time, they had to stay awake for around 40 hours while samples were collected at three-hourly intervals.

The results were compared with the effect on the same volunteers of sleeping up to 10 hours a night for a week. Again, samples were taken when volunteers stayed awake for a long period at the end of the study.

Originally posted here:
Lack Of Sleep Impacts On Gene Activity

Recommendation and review posted by Bethany Smith

February 26, 2013 - 18:15 AMT

PanARMENIAN.Net - A run of poor sleep can have a potentially profound effect on the internal workings of the human body, say UK researchers, according to BBC News.

The activity of hundreds of genes was altered when people's sleep was cut to less than six hours a day for a week.

Writing in the journal PNAS, the researchers said the results helped explain how poor sleep damaged health.

Heart disease, diabetes, obesity and poor brain function have all been linked to substandard sleep. What missing hours in bed actually does to alter health, however, is unknown.

So researchers at the University of Surrey analysed the blood of 26 people after they had had plenty of sleep, up to 10 hours each night for a week, and compared the results with samples after a week of fewer than six hours a night.

More than 700 genes were altered by the shift. Each contains the instructions for building a protein, so those that became more active produced more proteins - changing the chemistry of the body.

Meanwhile the natural body clock was disturbed - some genes naturally wax and wane in activity through the day, but this effect was dulled by sleep deprivation.

Prof Colin Smith, from the University of Surrey, told the BBC: "There was quite a dramatic change in activity in many different kinds of genes."

Areas such as the immune system and how the body responds to damage and stress were affected.

Here is the original post:
Poor sleep dramatically affects gene activity, research suggests

Recommendation and review posted by Bethany Smith

Public release date: 26-Feb-2013 [ | E-mail | Share ]

Contact: Bill Ferguson bferguson@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, February 26, 2013Mary Ann Liebert, Inc., publishers (http://www.liebertpub.com) announces the launch of MOOCs Forum (http://www.liebertpub.com/mooc) to serve as the host and chronicle for discussions, debates, announcements, and advancements for all issues and constituents in the Massive Open Online Courses community. The Journal will be published in print and online with Open Access options.

Multidisciplinary in scope, MOOCs Forum will be the public venue for examining key issues paramount to the success of MOOCs such as increasing course completion rates, course content and examination security, student identification, successful business models, and all evolving topics related to the field.

The Editor-in-Chief of MOOCs Forum is Jack M. Wilson, PhD, President Emeritus, the University of Massachusetts and Distinguished Professor of Higher Education, Emerging Technologies, and Innovation. Widely considered a thought leader, and sometimes critic, for MOOCs, Wilson was recently the keynote speaker at the University of Pennsylvania Higher Education Leadership Conference: Innovation in an Era of Disruptive Change, as well as delivering two keynotes on MOOCs at the recent annual meeting of the Association of American Colleges and Universities. Wilson states, "The sudden attention garnered by MOOCs is evidence of the rapidly changing environment for higher education. Over the last 10 years online learning and other technology driven innovations have begun a transformation of post-secondary education. Online enrollments passed 6 million in 2010 and were nearing 7 million by the end of 2011. MOOCs have attracted audiences of over 100,000 in a single course, but face challenges in retaining students to completion."

Key members of the Editorial Board include: Eren Bali, Udemy; Tom Do, Coursera; John Flores, United States Distance Learning Association; Nish Sonwalkar, MIT; Phil DiSalvio, University of Massachusetts, Boston; and Peter Lange, Duke University.

Company founder and CEO Mary Ann Liebert comments, "MOOCs are an important and growing resource with great promise to improve the education and consequently the quality of life for people everywhere. This Forum will accelerate the development, acceptance, and use of MOOCs by universities and their students, employers and employees, as well people committed to continuous learning around the world."

###

About the Publisher

Mary Ann Liebert, Inc., publishers (http://www.liebertpub.com) is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science, technology, and medicine including Big Data and Disruptive Science and Technology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's more than 70 journals, newsmagazines, and books is available on the Mary Ann Liebert, Inc., publishers (http://www.liebertpub.com) website.

The rest is here:
MOOCs Forum: The public venue for sharing and shaping developments in massive open online courses

Recommendation and review posted by Bethany Smith